Key highlights
- AI-powered antibody development: BigHat and Lilly will co-develop up to two antibody therapeutic programs using BigHat’s machine learning-driven Milliner™ platform to create next-gen antibodies with improved functionality.
- Strategic investment and support: Lilly will invest in BigHat and provide resources through its Catalyze360™ model, including funding, lab space, and drug development support.
- Clinical pipeline momentum: BigHat retains full global rights to its GI cancer antibody-drug conjugate (ADC) program, which is on track to enter clinical trials in 2026.
San Mateo, CA – BigHat Biosciences, a biotechnology company applying machine learning to antibody design and development, has entered into a strategic collaboration with Eli Lilly and Company to accelerate the creation of advanced antibody therapeutics.
Strategic collaboration leveraging AI-powered antibody design
The collaboration combines BigHat’s Milliner™ platform, an integrated AI/ML and synthetic biology system, with Lilly’s deep expertise in pharmaceutical R&D. Together, the two companies will co-develop up to two antibody programs aimed at enhancing therapeutic performance and improving drug-like properties such as stability, efficacy, and manufacturability.
Advanced platform to accelerate biologics innovation
BigHat’s Milliner platform merges state-of-the-art machine learning models with a high-speed wet lab, enabling the rapid design and iteration of therapeutic antibodies. This integrated approach allows for scalable development of biologics with improved functional and biophysical characteristics.
Equity investment and support through Lilly Catalyze360™
As part of the collaboration, Lilly will make an equity investment in BigHat. The alliance is supported through Lilly Catalyze360™, a framework designed to empower early-stage biotech startups. This model offers funding, infrastructure, and access to Lilly’s internal expertise via its three arms: Lilly Ventures, Gateway Labs®, and ExploR&D.
Pipeline expansion and oncology focus
In addition to the partnered programs, the agreement includes support for BigHat’s in-house ADC program targeting gastrointestinal cancers. This candidate is scheduled to enter clinical trials in 2026. BigHat retains full global rights and control over the program, underscoring its commitment to internal innovation in oncology and immunology.
Executive commentary on AI and drug discovery impact
“This collaboration brings together BigHat’s AI-powered platform and Lilly’s leadership in therapeutic innovation,” said Peyton Greenside, CEO and Co-founder of BigHat Biosciences. “Together, we aim to accelerate the development of transformative antibody therapeutics that can address significant patient needs.”
Expanding capabilities for AI in biologics
Both companies are committed to integrating AI and synthetic biology technologies to enhance the precision and speed of biologic drug development. The partnership is expected to deliver high-quality, differentiated protein therapeutics with the potential to improve treatment options for chronic diseases.
About BigHat Biosciences
BigHat Biosciences is a biotechnology company designing safer, more effective biologic therapies using machine learning and synthetic biology. Its AI-driven Milliner platform enables rapid antibody design and optimization. BigHat is advancing a pipeline of antibody-drug conjugates and T-cell engagers targeting oncology and inflammation. The company is backed by leading investors and has raised over $100 million.
About Eli Lilly and Company
Lilly is a global leader in pharmaceutical innovation, developing life-changing medicines in areas such as diabetes, cancer, Alzheimer’s disease, and immunology. With over 145 years of scientific excellence, Lilly is integrating AI and data science to accelerate therapeutic discovery and development.
By